Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported an automatic sale of 12,616 shares of common stock on February 4, 2026. The shares were sold at a weighted average price of $6.4419 per share to cover withholding taxes upon vesting of previously granted restricted stock units, under a durable automatic sale instruction letter.
After this tax-withholding sale, Dr. Brooks beneficially owns 84,092 shares of Solid Biosciences common stock in direct form. The company’s disclosure notes that the transaction did not represent a discretionary trade by Dr. Brooks, and that the individual sale prices ranged from $6.28 to $6.60 per share.
Solid Biosciences Inc. insider transaction: Chief Regulatory Officer Jessie Hanrahan reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, 12,348 shares of common stock were sold at a weighted average price of $6.4419 per share to cover withholding taxes after restricted stock units vested. The filing notes this was executed under a pre-established durable automatic sale instruction and is not a discretionary trade. After the transaction, Hanrahan beneficially owned 70,327 shares of Solid Biosciences common stock in direct ownership.
Solid Biosciences Inc. Chief Technology Officer Paul Herzich reported a small, routine share sale on a Form 4. On February 4, 2026, he sold 10,905 shares of common stock at a weighted average price of $6.4419 per share.
According to the filing, the sale was made solely to cover withholding taxes after previously granted restricted stock units vested, under a pre-established durable automatic sale instruction. It was not a discretionary trade. After this transaction, Herzich beneficially owned 69,067 shares directly.
Solid Biosciences insider files notice to sell shares. A person named Kevin Tan filed to sell 14,783 shares of Solid Biosciences common stock through E*TRADE, with an aggregate market value of $95,226.63, on or about 02/04/2026 on NASDAQ, with 82,569,192 shares outstanding.
The 14,783 shares come from vested restricted stock units that settled on 02/04/2026 as compensation from the issuer. Over the prior three months, Kevin Tan sold 5,704 shares for $30,060.08 on 01/13/2026 and 26,837 shares for $172,747.09 on 02/02/2026.
Solid Biosciences insider Paul Herzich has filed a notice under Rule 144 to sell 10,905 shares of the company’s common stock through E*TRADE on or about 02/04/2026, to be traded on NASDAQ. The aggregate market value of the planned sale is 70,246.73.
The shares to be sold were acquired the same day through settlement of vested restricted stock units as compensation from the issuer. The filing also reports that, over the past three months, Herzich sold 2,701 shares for gross proceeds of 13,802.11 and 26,250 shares for gross proceeds of 168,968.63.
Solid Biosciences insider Ilan Ganot has filed a Form 144 to sell common stock. The notice covers an intended sale of 7,205 shares of Solid Biosciences common stock through E*TRADE Financial Corporation on or about February 4, 2026, with an aggregate market value of $46,411.95. These shares were acquired the same day via settlement of vested restricted stock units, held indirectly through his wife, as compensation from the issuer. Over the prior three months, Ganot reported additional sales of 3,278, 1,053 and 191 shares of common stock, generating gross proceeds of $13,505.36, $5,717.79 and $1,258.69, respectively.
Solid Biosciences insider Alexander Cumbo has filed a Form 144 indicating an intention to sell 48,913 shares of common stock through E*TRADE, with an aggregate market value of $315,079.69. The planned sale date is listed as 02/04/2026, on the NASDAQ market, and the filing notes 82,569,192 shares outstanding.
The shares to be sold were acquired on 02/04/2026 through settlement of vested restricted stock units as compensation from the issuer. Over the past three months, Cumbo has sold 10,808 shares for $55,228.88 on 12/03/2025 and 80,258 shares for $516,612.72 on 02/02/2026.
Solid Biosciences insider David T. Howton filed a Rule 144 notice to sell 18,894 shares of common stock through E*TRADE Financial on NASDAQ, with an aggregate market value of $121,708.27.
These shares were acquired on 02/04/2026 via settlement of vested restricted stock units as compensation. Over the prior three months, Howton sold 4,932 shares for $25,202.52 on 12/03/2025 and 37,771 shares for $243,128.15 on 02/02/2026.
An insider of the issuer filed a notice to sell 12,348 shares of common stock under Rule 144. These shares are to be sold through ETRADE Financial Corporation on NASDAQ, with an aggregate market value of 79,541.32 and 82,569,192 shares of the same class outstanding.
The shares were acquired on 02/04/2026 through settlement of vested restricted stock units as compensation from the issuer. The same person previously sold 4,483 shares for 22,908.13 on 12/03/2025 and 26,535 shares for 170,803.14 on 02/02/2026.
Solid Biosciences shareholder Brooks Gabriel filed a Rule 144 notice to sell 12,616 shares of common stock through E*TRADE on NASDAQ, with an aggregate market value of $81,267.65. The filing shows 82,569,192 shares of common stock outstanding.
The 12,616 shares were acquired the same day via settlement of vested restricted stock units as compensation from the issuer. The notice also reports that Gabriel sold 28,335 shares of common stock in a prior transaction on 02/02/2026, generating gross proceeds of $182,389.56.